Patents Assigned to International Institute of Cancer Immunology, Inc.
-
Patent number: 9851356Abstract: Provided is an invention relating to a method for measuring an anti-WT1 antibody in a sample allowing measurement and evaluation of the anti-WT1 antibody with higher accuracy and to use of the method.Type: GrantFiled: September 13, 2012Date of Patent: December 26, 2017Assignees: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC., OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Haruo Sugiyama, Yusuke Oji, Kiyonori Katsuragi, Hideaki Tanaka, Shinji Sogo, Yoshihiro Goto, Yasukazu Ohmoto, Husako Iwata
-
Patent number: 9833493Abstract: The present invention relates to a method for activating helper T cells, which includes the step of activating helper T cells by adding a WT1 peptide to antigen presenting cells, wherein the WT1 peptide has the ability to bind to an MHC class II molecule selected from HLA-DRB1*08:02 molecule, an HLA-DRB1*13:02 molecule, an HLA-DRB1*14:03 molecule, an HLA-DRB1*14:05 molecule, an HLA-DQB1*03:02 molecule, and an HLA-DQB1*04:01 molecule.Type: GrantFiled: December 16, 2013Date of Patent: December 5, 2017Assignee: International Institute of Cancer Immunology, Inc.Inventors: Hiroshi Kubo, Shinji Sogo, Haruo Sugiyama
-
Patent number: 9803246Abstract: The invention provides the nucleotide sequence and amino acid sequence of the CDR3 domain of the T cell receptor (TCR) gene of a WT1-specific cytotoxic T cell (CTL) against WT1 protein. Also provided are a method for testing for and treating cancer using the nucleotide sequence and amino acid sequence, and a chip, primer set, kit, and device for testing for cancer comprising the nucleotide sequence and amino acid sequence.Type: GrantFiled: June 20, 2012Date of Patent: October 31, 2017Assignee: International Institute of Cancer Immunology, Inc.Inventor: Haruo Sugiyama
-
Patent number: 9765114Abstract: A novel compound of the formula (1): wherein X is a tyrosine residue or a methionine residue; Y and Z each are a single bond or the like; R1 is a hydrogen atom or the like; R2 is a hydroxy group or the like; R3 is a hydrogen atom, alkyl group, amino group or the like; R4 is a hydrogen atom, alkyl group, carboxy group or the like; m is 1 or 2; and n is an integer of 0 to 2, with the proviso that when n is 0, R3 is a hydrogen atom or an alkyl group, or a pharmaceutically acceptable salt thereof, and its use in cancer immunotherapy.Type: GrantFiled: February 26, 2016Date of Patent: September 19, 2017Assignees: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC., SUMITOMO DAINIPPON PHARMA CO., LTD.Inventors: Toshio Nishihara, Masashi Gotoh
-
Publication number: 20170232089Abstract: A cancer vaccine composition for human leukocyte antigen (HLA)-A*0206-positive persons, comprising a protein product of the tumor suppressor gene WT1 or a partial peptide thereof.Type: ApplicationFiled: December 16, 2016Publication date: August 17, 2017Applicant: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.Inventor: Haruo Sugiyama
-
Publication number: 20170138958Abstract: Provided is an invention relating to a method for measuring an anti-WT1 antibody in a sample allowing measurement and evaluation of the anti-WT1 antibody with higher accuracy and to use of the method.Type: ApplicationFiled: December 8, 2016Publication date: May 18, 2017Applicants: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC., OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Haruo SUGIYAMA, Yusuke OJI, Kiyonori KATSURAGI, Hideaki TANAKA, Shinji SOGO, Yoshihiro GOTO, Yasukazu OHMOTO, Husako IWATA
-
Publication number: 20170072038Abstract: The present invention relates to combination therapy for cancer with a WT1 peptide vaccine and temozolomide.Type: ApplicationFiled: December 1, 2016Publication date: March 16, 2017Applicant: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.Inventors: Haruo SUGIYAMA, Toshiki Yoshimine, Akihiro Tsuboi, Naoya Hashimoto
-
Patent number: 9539299Abstract: The present invention relates to combination therapy for cancer with a WT1 peptide vaccine and temozolomide.Type: GrantFiled: October 31, 2012Date of Patent: January 10, 2017Assignee: International Institute of Cancer Immunology, Inc.Inventors: Haruo Sugiyama, Toshiki Yoshimine, Akihiro Tsuboi, Naoya Hashimoto
-
Publication number: 20160367649Abstract: A cancer vaccine composition for human leukocyte antigen (HLA)-A*0206-positive persons, comprising a protein product of the tumor suppressor gene WT1 or a partial peptide thereof.Type: ApplicationFiled: February 25, 2015Publication date: December 22, 2016Applicant: International Institute of Cancer Immunology, Inc.Inventor: Haruo SUGIYAMA
-
Publication number: 20160243209Abstract: A tumor antigen that comprises, as an active ingredient, a product of the Wilms' tumor suppressor gene WT1 or a peptide composed of 7-30 contiguous amino acids containing an anchor amino acid for binding to major histocompatibility complex (MHC) class I in said amino acid sequence, and a vaccine comprising said antigen.Type: ApplicationFiled: April 5, 2016Publication date: August 25, 2016Applicant: International Institute of Cancer Immunology, Inc.Inventors: Haruo SUGIYAMA, Yoshihiro Oka
-
Patent number: 9403886Abstract: A tumor antigen that comprises, as an active ingredient, a product of the Wilms' tumor suppressor gene WT1 or a peptide composed of 7-30 contiguous amino acids containing an anchor amino acid for binding to major histocompatibility complex (MHC) class I in said amino acid sequence, and a vaccine comprising said antigen.Type: GrantFiled: July 29, 2008Date of Patent: August 2, 2016Assignee: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.Inventors: Haruo Sugiyama, Yoshihiro Oka
-
Publication number: 20160168197Abstract: A novel compound of the formula (1): wherein X is a tyrosine residue or a methionine residue; Y and Z each are a single bond or the like; R1 is a hydrogen atom or the like; R2 is a hydroxy group or the like; R3 is a hydrogen atom, alkyl group, amino group or the like; R4 is a hydrogen atom, alkyl group, carboxy group or the like; m is 1 or 2; and n is an integer of 0 to 2, with the proviso that when n is 0, R3 is a hydrogen atom or an alkyl group, or a pharmaceutically acceptable salt thereof, and its use in cancer immunotherapy.Type: ApplicationFiled: February 26, 2016Publication date: June 16, 2016Applicants: International Institute of Cancer Immunology, Inc., Chugai Seiyaku Kabushiki Kaisha, Dainippon Sumitomo Pharma Co., Ltd.Inventors: Toshio NISHIHARA, Masashi Gotoh
-
Publication number: 20160114019Abstract: A compound represented by the formula (1): wherein Xa and Ya are each a single bond and the like, cancer antigen peptide A is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, R1 is a hydrogen atom, a group represented by the formula (2): wherein Xb and Yb are each a single bond and the like, cancer antigen peptide B has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, or cancer antigen peptide C, and cancer antigen peptide C has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide or an MHC class II-restricted WT1 peptide, consisting of 7-30 amino acid residues containing one cysteine residue, or a salt thereof, and the like.Type: ApplicationFiled: December 30, 2015Publication date: April 28, 2016Applicants: SUMITOMO DAINIPPON PHARMA CO., LTD., INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.Inventors: Chiang Jia Li, Hitoshi Ban, Yukihiro Nishio, Masashi Goto, Toshio Nishihara, Yosuke Takanashi
-
Patent number: 9315865Abstract: Disclosed are: a nucleotide sequence and an amino acid sequence for CDR3 region of T-cell receptor (TCR) gene of WT1-specific cytotoxic T-cell (CTL) for WT1 protein; a method for the detection or treatment of cancer using the nucleotide sequence or the amino acid sequence; and a chip, a primer set, a kit, an apparatus and the like for use in the detection of cancer, each of which comprises the nucleotide sequence or the amino acid sequence.Type: GrantFiled: February 28, 2008Date of Patent: April 19, 2016Assignee: International Institute of Cancer Immunology, Inc.Inventor: Haruo Sugiyama
-
Patent number: 9272026Abstract: An HLA-A*1101-restricted WT1 peptide, specifically, a peptide comprising an amino acid sequence consisting of 9 contiguous amino acids from a WT1 protein, wherein the peptide has an ability to bind to an HLA-A*1101 molecule, and has an ability to induce a CTL is described. A peptide dimer having an ability to bind to an HLA-A*1101 molecule and having an ability to induce a CTL, in which two peptide monomers each comprising an amino acid sequence consisting of 9 contiguous amino acids from a WT1 protein and comprising at least one cysteine residue are bound to each other through a disulfide bond is also described. Furthermore, a polynucleotide encoding the peptide, a pharmaceutical composition for the treatment and/or prevention of a cancer comprising the same and the like are provided.Type: GrantFiled: December 26, 2013Date of Patent: March 1, 2016Assignee: International Institute of Cancer Immunology, Inc.Inventor: Haruo Sugiyama
-
Patent number: 9273148Abstract: A novel compound of the formula (1): wherein X is a tyrosine residue or a methionine residue; Y and Z each are a single bond or the like; R1 is a hydrogen atom or the like; R2 is a hydroxy group or the like; R3 is a hydrogen atom, alkyl group, amino group or the like; R4 is a hydrogen atom, alkyl group, carboxy group or the like; m is 1 or 2; and n is an integer of 0 to 2, with the proviso that when n is 0, R3 is a hydrogen atom or an alkyl group, or a pharmaceutically acceptable salt thereof, and its use in cancer immunotherapy.Type: GrantFiled: September 10, 2013Date of Patent: March 1, 2016Assignees: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC., CHUGAI SEIYAKU KABUSHIKI KAISHA, SUMITOMO DAINIPPON PHARMA CO., LTD.Inventors: Toshio Nishihara, Masashi Gotoh
-
Publication number: 20160051652Abstract: The present invention provides a method for detecting cancer using a protein expressed in various cancers, and a pharmaceutical composition for the treatment or prevention of such cancer using the protein as an indicator. Furthermore, the present invention provides a pharmaceutical composition containing a cancer antigen peptide derived from the protein. More particularly, the method comprises the step of determining the presence or amount of an eEF2 polypeptide or an eEF2 antibody in a sample obtained from a subject.Type: ApplicationFiled: August 27, 2015Publication date: February 25, 2016Applicant: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.Inventors: Haruo SUGIYAMA, Yusuke OJI
-
Patent number: 9266932Abstract: The present invention relates to a WT1 peptide which has an amino acid sequence consisting of contiguous amino acids derived from a WT1 protein and induces WT1-specific helper T cells by binding to an MHC class II molecule, a pharmaceutical composition comprising them and the like.Type: GrantFiled: April 22, 2010Date of Patent: February 23, 2016Assignee: International Institute of Cancer Immunology, Inc.Inventor: Haruo Sugiyama
-
Patent number: 9248173Abstract: A compound represented by the formula (1): wherein Xa and Ya are each a single bond and the like, cancer antigen peptide A is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, R1 is a hydrogen atom, a group represented by the formula (2): wherein Xb and Yb are each a single bond and the like, cancer antigen peptide B has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, or cancer antigen peptide C, and cancer antigen peptide C has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide or an MHC class II-restricted WT1 peptide, consisting of 7-30 amino acid residues containing one cysteine residue, or a salt thereof, and the like.Type: GrantFiled: May 7, 2015Date of Patent: February 2, 2016Assignees: SUMITOMO DAINIPPON PHARMA CO., LTD., INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.Inventors: Chiang Jia Li, Hitoshi Ban, Yukihiro Nishio, Masashi Goto, Toshio Nishihara, Yosuke Takanashi
-
Publication number: 20150361147Abstract: The present invention provides a method for detecting cancer using a protein expressed in various cancers, and a pharmaceutical composition for the treatment or prevention of such cancer using the protein as an indicator. Furthermore, the present invention provides a pharmaceutical composition containing a cancer antigen peptide derived from the protein. More particularly, the method comprises the step of determining the presence or amount of an eEF2 polypeptide or an eEF2 antibody in a sample obtained from a subject.Type: ApplicationFiled: August 27, 2015Publication date: December 17, 2015Applicant: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.Inventors: Haruo SUGIYAMA, Yusuke OJI